Resumen: Incyte presenta datos de dosis múltiples de fase 1/2 para VGA039 (latarcibart) en ISTH 2026 que muestran reducciones sustanciales de sangrado en pacientes con todos los tipos de enfermedad de von Willebrand
Tuesday, July 14, 2026 BiopharmaWatch Research 1 min read
Key Takeaway: Incyte has announced positive results from a Phase 1/2 multiple dose study of VGA039 (latarcibart), a monoclonal antibody targeting protein S for patients with von Willebrand disease. The data, presented at ISTH 2026, showed substantial reductions in bleeding across all types of the disease. The study included safety and efficacy data from 16 enrolled patients.
Price reaction · baseline $114.23 (2026-07-13 close) · hit pre-market · 3 other INCY headline(s) in the window, move may be shared
day 0 close · peak
+0.6%
Market Sentiment Analysis
POSITIVE FACTORS
Significant reductions in bleeding observed in all patient types.
Data presented at ISTH 2026 highlights the efficacy of VGA039.
Study involved comprehensive safety and efficacy data from 16 patients.
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+44%
120-day peak, hindsight
Typical move
1.8%
average across 15 past catalysts
Lead asset
INCB013739
Phase 2 · Type 2 Diabetes
Full Press Release Details
WILMINGTON, Del.--(BUSINESS WIRE)--Incyte (Nasdaq: INCY) anunció hoy datos de seguridad y eficacia completos de todos los pacientes (n=16) inscritos en el estudio de dosis múltiples de fase 1/2 de VGA039 (latarcibart), un nuevo anticuerpo monoclonal en investigación dirigido a la proteína S para pacientes con enfermedad de von Willebrand (VWD). El comunicado en el idioma original es la versión oficial y autorizada del mismo. Esta traducción es solamente un medio de ayuda y deberá ser comparada
Frequently Asked Questions
What is VGA039?
VGA039, also known as latarcibart, is a monoclonal antibody targeting protein S.
What disease does VGA039 target?
VGA039 is aimed at treating von Willebrand disease (VWD).
What were the results of the Phase 1/2 study?
The study showed significant reductions in bleeding across all patient types.
How many patients were involved in the study?
The study included 16 patients enrolled for safety and efficacy assessment.
Where were the results presented?
The results were presented at the ISTH 2026 conference.